Home » Posts tagged 'michael bradfield'

Tag Archives: michael bradfield

Advanced Oncotherapy (AVO) – Additional financing agreement

Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that on Tuesday 25 April it drew down a further £2 million as part of the 12-month convertible and redeemable loan agreement announced on 27 March 2017 with Blackfinch Investment Ltd, through its subsidiary Henslow Trading Limited. This brings the total financing from Blackfinch to £5 million. This additional £2 million facility is issued on the same terms as the initial £3 million loan announced on 27 March 2017.

Terms of the Loan Agreement

  • 1 year loan
  • £5m loan in total now fully drawn down
  • Interest rate of 11%
  • Repayment in cash at maturity, or possibility at discretion of the lender at any time within the next 12 months to convert all or part of the loan into Advanced Oncotherapy shares at a conversion price of 100p per share

Loan security

The £5 million loan is secured on the Company’s lease for 141-143, Harley Street and on certain other equipment of the Company. Should the Company not meet its obligations under the Loan Agreement and after a four month period during which the lease is offered for sale, four shareholders and directors (the “Guarantors”) of the Company, being Dr Nick Plowman, Fairford Capital (a company 100 per cent. owned by Michael Bradfield) and Professor Chris Nutting, in addition to Michael Sinclair who, as announced on 27 March 2017, had already provided an offer to buy back the lease, have agreed with Blackfinch to buy back the lease at a value equivalent to the outstanding amount of the £5m loan plus accrued interests and expenses. The Guarantors have also undertaken to the Company that, should they be required to buy back the lease from Blackfinch, they will offer the then shareholders of the Company the opportunity to participate in the buy back on the same terms as their participation pro rata for their shareholding in the Company.

Related party transactions

The offers by Nick Plowman, Fairford Capital and Chris Nutting to buy back the lease from Blackfinch which is part of the loan agreement with Blackfinch constitute transactions with related parties under the AIM Rules for Companies.  In accordance, therefore, with the AIM Rules, the directors of the Company, with the exclusion of Nick Plowman, Michael Bradfield  and Chris Nutting and Michael Sinclair, who had also made an offer to Blackfinch to buy back the lease as set out in the announcement of 27 March 2017, having consulted with the Company’s nominated adviser, Stockdale Securities Limited, consider that the terms of Nick Plowman, Fairford Capital and Chris Nutting entering into the agreement with Blackfinch are fair and reasonable insofar as the Company’s shareholders are concerned.

For further information, please contact:

Advanced Oncotherapy plc www.avoplc.com
Nicolas Serandour, Chief Executive Officer Tel: +44 20 3617 8728
Michael Sinclair, Executive Chairman
Stockdale Securities (Nomad & Joint Broker) Tel: +44 20 7601 6100
Antonio Bossi / David Coaten
Stifel Nicolaus Europe (Joint Broker) Tel: +44 20 7710 7600
Jonathan Senior / Ben Maddison
Walbrook PR (Financial PR & IR) Tel: +44 20 7933 8780 or avo@walbrookpr.com
Paul McManus Mob: +44 7980 541 893
Anna Dunphy Mob: +44 7876 741 001

About Advanced Oncotherapy plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac for Image Guided Hadron Therapy (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

About Blackfinch www.blackfinch.com

Blackfinch is an established UK provider of tax-efficient investment solutions. Their philosophy is based on transparency and simplicity and their services provide real solutions to real financial planning challenges faced by individuals today

Advanced Oncotherapy (AVO) – Director Dealing

AVO1Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed yesterday that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 30,000 ordinary shares of 25 pence each in the Company at an average price of 135.0 pence per Ordinary Share.

Following this transaction, Michael Bradfield now holds 5,080,740 Ordinary Shares representing 8.95% of the issued share capital of the Company.

For further information, please contact:

Advanced Oncotherapy plc

www.avoplc.com

Michael Sinclair, Chief Executive Officer

Tel: +44 20 3617 8728

Nicolas Serandour, Chief Operating and Financial Officer

Stockdale Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Jon Belliss / Elliot Hance

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus

Mob: +44 7980 541 893

About Advanced Oncotherapy plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy systems with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy’s team “ADAM” based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (“LIGHT”). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a fraction of the size and significantly lower in cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

The Company has signed two purchase agreements with Sinophi Healthcare Limited for the LIGHT proton therapy systems to be installed in hospitals in China. There are also four additional framework agreements and further Letters of Intent from other healthcare providers.

The Company has also signed a joint venture agreement with CircleHealth, owned by AIM-listed Circle Holdings plc, to operate the Company’s proton beam cancer therapy centre in Harley Street.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

Advanced Oncotherapy (AVO) – Director Dealing

AVO1Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed on Friday 8 July 2016 that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, on Friday 8 July 2016 purchased 10,000 ordinary shares of 25 pence each in the Company (“Ordinary Shares”) at 119.50 pence per Ordinary Share.

Following this transaction, Michael Bradfield now holds 5,050,740 Ordinary Shares representing 8.90% of the issued share capital of the Company.

For further information, please contact:

Advanced Oncotherapy plc

www.avoplc.com

Michael Sinclair, Chief Executive Officer

Tel: +44 20 3617 8728

Nicolas Serandour, Chief Operating and Financial Officer

Stockdale Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Jon Belliss / Elliot Hance

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus

Mob: +44 7980 541 893

 

About Advanced Oncotherapy plc www.avoplc.com

 

Advanced Oncotherapy is a provider of particle therapy systems with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy’s team “ADAM” based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (“LIGHT”). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a fraction of the size and significantly lower in cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

The Company has signed two purchase agreements with Sinophi Healthcare Limited for the LIGHT proton therapy systems to be installed in hospitals in China. There are also four additional framework agreements and further Letters of Intent from other healthcare providers.

The Company has also signed a joint venture agreement with CircleHealth, owned by AIM-listed Circle Holdings plc, to operate the Company’s proton beam cancer therapy centre in Harley Street. 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

Advanced Oncotherapy (AVO) – Director Dealing

AVO1Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed yesterday that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 10,000 ordinary shares of 25 pence each in the Company at 112.0 pence per Ordinary Share.

Following this transaction, Michael Bradfield now holds 5,040,740 Ordinary Shares representing 8.88% of the issued share capital of the Company.

For further information, please contact:

Advanced Oncotherapy plc

www.avoplc.com

Michael Sinclair, Chief Executive Officer

Tel: +44 20 3617 8728

Nicolas Serandour, Chief Operating and Financial Officer

Stockdale Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Jon Belliss / Elliot Hance

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus

Mob: +44 7980 541 893

About Advanced Oncotherapy plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy systems with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy’s team “ADAM” based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (“LIGHT”). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a fraction of the size and significantly lower in cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

The Company has signed two purchase agreements with Sinophi Healthcare Limited for the LIGHT proton therapy systems to be installed in hospitals in China. There are also four additional framework agreements and further Letters of Intent from other healthcare providers.

The Company has also signed a joint venture agreement with CircleHealth, owned by AIM-listed Circle Holdings plc, to operate the Company’s proton beam cancer therapy centre in Harley Street. 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

Advanced Oncotherapy (AVO) – Director Dealing

AVO1Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed yesterday that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 50,000 ordinary shares of 25 pence each in the Company at 102.5 pence per Ordinary Share.

Following this transaction, Michael Bradfield now holds 5,030,740 Ordinary Shares representing 8.86% of the issued share capital of the Company.

For further information, please contact:

Advanced Oncotherapy plc

www.avoplc.com

Michael Sinclair, Chief Executive Officer

Tel: +44 20 3617 8728

Nicolas Serandour, Chief Operating and Financial Officer

Stockdale Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Jon Belliss / Elliot Hance

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus

Mob: +44 7980 541 893

About Advanced Oncotherapy plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy systems with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy’s team “ADAM” based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (“LIGHT”). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a fraction of the size and significantly lower in cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

The Company has signed two purchase agreements with Sinophi Healthcare Limited for the LIGHT proton therapy systems to be installed in hospitals in China. There are also four additional framework agreements and further Letters of Intent from other healthcare providers.

The Company has also signed a joint venture agreement with CircleHealth, owned by AIM-listed Circle Holdings plc, to operate the Company’s proton beam cancer therapy centre in Harley Street. 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

Advanced Oncotherapy (AVO) secures of £24m financing for Harley Street

AVO1Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed an agreement with a fund advised by Metric Capital Partners LLP, a pan-European private capital fund manager, whereby Metric Capital will invest £24 million in a financing facility to support the Company’s provision of vendor financing for the installation of Advanced Oncotherapy’s first LIGHT machine in Harley Street.  

On 12 October 2015, the Company announced the establishment of a proton beam cancer therapy centre in Harley Street. Funding for the clinic, the London Proton Therapy Centre Limited, will come from the Company and its partners in equal amounts in the form of equity totalling £6 million and the provision of a vendor loan from Advanced Oncotherapy to LPTC.

The Agreement is subject to customary representations, undertakings and events of default and includes financial covenants relating to the future cash balances, revenues and profitability of Advanced Oncotherapy, and to the profitability of LPTC as well as a number of non-financial covenants relating to technological development, delivery of the first LIGHT system and first patient treatment. The Company will pay a cash interest of 250 basis points per annum above 3 month LIBOR (subject to a minimum LIBOR of 150 basis points) payable quarterly and payment in kind (“PIK”) interest of 850 basis points payable at maturity or convertible into ordinary Advanced Oncotherapy shares (“Ordinary Shares”) at 10p per Ordinary Share (subject to customary adjustments for convertible instruments). In addition, the Company has agreed to issue to Metric Capital each year during the life of the Agreement warrants over 14.5 million Ordinary Shares exercisable at 16p per Ordinary Share. The Agreement has a term of 5 years and requires any future equity capital injections to be carried out on terms similar to or better than the conversion rights of the PIK interest described above.

Of the £24 million financing, £11 million will be received shortly following signing. The second tranche of £13 million will be available for drawdown on completion of a £25 million cash or capital injection to fund the development of a manufacturing base. Should these milestones not be achieved by the end of March 2017, the initial £11 million tranche will become repayable by September 2017. 

Metric Capital requires guarantees from certain directors and shareholders of the Company in order to enter into the Agreement; as a result, Michael Sinclair (Chief Executive Officer), Michael Bradfield (Non-Executive Director), Brahma AG (19.3% shareholder of the Company) alongside two other guarantors have agreed to provide guarantees to Metric Capital for a total of £2.5 million. There are various covenants attached to these guarantees concerning the timing of the delivery of various components of the Harley Street project and treatment of the first patients. In consideration for the provision of these guarantees, the Guarantors have entered into a Guarantee Fee Deed with the Company, under which they will each receive 3% of the net profits of LPTC attributable to the Company (Advanced Oncotherapy is expected to have an interest of approximately 50% in LPTC at the start of operations) for a period of ten years commencing on the first year in which LPTC will generate a positive net profit and with cash payments commencing once all amounts under the Agreement have been repaid.

The Company and Metric Capital are exploring opportunities for further investment to facilitate the provision of vendor financing to AVO customers both in the UK and overseas. 

Metric Capital will have the right to consent to certain reserved matters and the right to appoint a director to the Board of both Advanced Oncotherapy and LPTC and, in certain circumstances ADAM SA, a wholly owned subsidiary of Advanced Oncotherapy.

Nicolas Serandour, COO and CFO of Advanced Oncotherapy, commented: “We are delighted to have secured this financing partnership with Metric Capital. Vendor financing has become standard practice in the Proton Therapy Sector and this forms an essential part of our financial strategy, giving us greater confidence to secure new purchase orders and enhancing our returns. I am very pleased to have Metric Capital as our financing partner of choice and their support after extensive due diligence is a great endorsement of our technology and business plan. With the strong backing of Metric Capital and operating partners including Thales, Toshiba and VDL, we are uniquely positioned to deliver on our financing and execution strategy.”

John Sinik, Managing Partner of Metric Capital, said: “Advanced Oncotherapy represents a unique investment opportunity for Metric Capital. The proven technology developed over decades, coupled with the clear clinical need for the Company’s LIGHT machine, create an exciting backdrop for Metric Capital in supporting Advanced Oncotherapy’s growth. We have been very impressed with the Advanced Oncotherapy team, with their development partners and their achievements to date and look forward to supporting them as they make readily available a form of cancer treatment that can change the lives of thousands of patients a year in the UK and around the world.”

Related party transaction

The entering into the Guarantee Fee Deed with Michael Sinclair (Chief Executive Officer of the Company), Michael Bradfield (Non-Executive Director of the Company) and Brahma AG (a substantial shareholder of the Company) constitutes a related party transaction under the AIM Rules for Companies. In accordance with the AIM Rules, the independent directors of the Company, having consulted with the Company’s nominated adviser, Stockdale Securities Limited, consider that the terms of the Guarantee Fee Deed are fair and reasonable insofar as the Company’s shareholders are concerned. 

Advanced Oncotherapy Plc

www.avoplc.com

Michael Sinclair, Chief Executive Officer

Tel: +44 20 3617 8728

Nicolas Serandour, Chief Operating and Financial Officer

Stockdale Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Jon Belliss / Elliot Hance

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

 

About Metric Capital www.metric-capital.com

Metric Capital Partners LLP is a pan-European private capital fund manager providing bespoke capital solutions in special situations. Metric’s funds manage approximately €700 million of capital on behalf of a global institutional investor base. Since 2012, the firm has completed 18 transactions in 10 European jurisdictions, spanning a wide variety of industries and situations (from the refinancing of a container port in Sweden to the rescue financing of the leading supplementary education provider in France and growth capital for an Irish healthcare operator). 

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM” based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons. 

Advanced Oncotherapy – Additional Director Dealing

AVO1Advanced Oncotherapy (AVO) announces that Michael Sinclair, Executive Chairman of the Company, on 18 December 2015 purchased 500,000 ordinary shares of 1 penny each in the Company at 6.25 pence per Ordinary Share.

The Company also announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, on 18 December 2015 purchased 750,000 Ordinary Shares at 6.75 pence per Ordinary Share.

Following the above transactions, Michael Sinclair now holds 90,079,757 Ordinary Shares representing 6.35% of the issued share capital of the Company and Michael Bradfield now holds 124,518,510 Ordinary Shares representing 8.78% of the issued share capital of the Company.

.

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya, CEO

Tel: +44 20 3617 8728

Nicolas Serandour, CFO

Westhouse Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Jon Levinson / Elliot Hance

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Brand Communications

Alan Green

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

Tel: +44 1273 704473

Mob: +44 7976 431608

Advanced Oncotherapy – Additional Director Dealing

AVO1Advanced Oncotherapy (AVO) announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 1,000,000 ordinary shares of 1 penny each in the Company at 5.75 pence per Ordinary Share.

Following this transaction, Michael Bradfield now holds 123,768,510 Ordinary Shares representing 8.73% of the issued share capital of the Company.

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya, CEO

Tel: +44 20 3617 8728

Nicolas Serandour, CFO

Westhouse Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Jon Levinson / Elliot Hance

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Brand Communications

Alan Green

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

Tel: +44 1273 704473

Mob: +44 7976 431608

Advanced Oncotherapy – Director Dealing

AVO1Advanced Oncotherapy (AVO) announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 750,000 ordinary shares of 1 penny each in the Company at 5.5 pence per Ordinary Share.

Following this transaction, Michael Bradfield now holds 122,768,510 Ordinary Shares representing 8.66% of the issued share capital of the Company.

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya, CEO

Tel: +44 20 3617 8728

Nicolas Serandour, CFO

Westhouse Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Jon Levinson / Elliot Hance

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Brand Communications

Alan Green

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

Tel: +44 1273 704473

Mob: +44 7976 431608

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.